By Ellen Capon (Drug Target Review)2023-10-17T16:00:14
Research into how the amino acid arginine drives metabolic reprogramming offers promise for liver cancer treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2024-01-09T09:30:19
Sponsored by Sartorius
2023-02-23T14:02:18
Sponsored by bit.bio
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-11-24T12:06:45
Sponsored by Quantum-Si
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
Site powered by Webvision Cloud